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The International Rescue Committee, New York, NY, USA
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Abstract
The Zika virus (ZIKV) is a flavivirus of the family , which is similar toFlaviviridae
dengue virus, yellow fever and West Nile virus. Recent outbreaks in South
America, Latin America, the Caribbean and in particular Brazil have led to
concern for the spread of the disease and potential to cause Guillain-Barré
syndrome and microcephaly. Although ZIKV has been known of for over 60
years there is very little in the way of knowledge of the virus with few
publications and no crystal structures. No antivirals have been tested against it
either  or . ZIKV therefore epitomizes a neglected disease. Severalin vitro in vivo
suggested steps have been proposed which could be taken to initiate ZIKV
antiviral drug discovery using both high throughput screens as well as
structure-based design based on homology models for the key proteins. We
now describe preliminary homology models created for NS5, FtsJ, NS4B,
NS4A, HELICc, DEXDc, peptidase S7, NS2B, NS2A, NS1, E stem,
glycoprotein M, propeptide, capsid and glycoprotein E using SWISS-MODEL.
Eleven out of 15 models pass our model quality criteria for their further use.
While a ZIKV glycoprotein E homology model was initially described in the
immature conformation as a trimer, we now describe the mature dimer
conformer which allowed the construction of an illustration of the complete
virion. By comparing illustrations of ZIKV based on this new homology model
and the dengue virus crystal structure we propose potential differences that
could be exploited for antiviral and vaccine design. The prediction of sites for
glycosylation on this protein may also be useful in this regard. While we await a
cryo-EM structure of ZIKV and eventual crystal structures of the individual
proteins, these homology models provide the community with a starting point
for structure-based design of drugs and vaccines as well as a for computational
virtual screening.
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Introduction
All flaviviruses are spherical and contain a genome of approxi-
mately 11kb that functions as mRNA and encodes a polyprotein 
that leads to 10 proteins1. Examples include dengue virus, yellow 
fever and West Nile virus2. The recent pandemic of ZIKV occur-
ring in South America, Latin America, the Caribbean and in par-
ticular Brazil spread by the Aedes mosquito has awakened dormant 
interest in this flavivirus which is a mild dengue-like disease3. 
However several documented cases of Guillain-Barré syndrome 
and other neurologic conditions represent important complications 
of the disease. In recent weeks the extent of the disease has also 
become apparent as new discoveries and announcements are made 
almost daily. Though clearly we have a considerable number of 
significant gaps in our knowledge which need addressing4.
The most concerning issue however is microcephaly observed in 
women who had ZIKV during pregnancy. There have been multiple 
cases of ZIKV found in fetal or newborn brain tissue that had signs 
of prenatal damage. The virus seems to have neurotropism in fetal 
brains, which may account for the presumed association between 
the infection and microcephaly5,6. The fetus in the recent case study 
had microcephaly with calcifications and ZIKV was found in the 
brain6. The ZIKV strain was identified as from French Polynesia 
(GenBank accession number KJ776791) and several polymor-
phisms were noted in the NS1, NS4B and FtsJ like methyltrans-
ferase regions. While the findings are not absolute proof that ZIKV 
causes microcephaly, the evidence from this case report strengthens 
the linkage7. Experts involved in the decision on the World Health 
Organization determined Public Health Emergency of International 
Concern (PHEIC) recommended the need for more research into the 
microcephaly link and need for an animal model to be developed. 
This group also interestingly called for open data sharing8. Early 
work 45 years ago in inoculated newborn mice showed that ZIKV 
had neurological effects, enlarging astroglial cells and destroying 
pyriform cells. At the same time virus formation within the endo-
plasmic reticulum was also visualized9. We are not aware of any 
studies of effects of ZIKV on human brain or brain cells. Locali-
zation of such viruses to the brain is not unusual for flaviviruses 
i.e. West Nile virus and this tropism may arise from viral binding 
to glycosaminoglycans, as has been observed for dengue virus in 
human microvascular endothelial cells10. Heparan sulfate and the 
C-type lectin DC-SIGN (dendritic cell-specific intercellular adhe-
sion molecule 3-grabbing nonintegrin) are well characterized 
attachment structures for flaviviruses on cells. Interfering with 
glycan binding is one potential approach to preventing virus entry. 
Another is to acidify the endosome as has been demonstrated 
in vitro with chloroquine for dengue virus infection2. Several entry 
and adhesion factors, including DC-SIGN, Tyro3, and AXL as well 
as others, have been shown to permit ZIKV entry in human skin 
cells11.
The routes for transmission of ZIKV besides mosquito are of some 
concern. Recent US CDC guidance to pregnant women describes 
precautions against sexual transmission of ZIKV12 and that the 
virus can persist for up to 12 weeks13. Possible ZIKV transmission 
through blood transfusion in French Polynesia was described by 
detecting the virus in 3% of asymptomatic blood donors14. Given 
how widespread ZIKV has become, there is a risk of depleting the 
blood supply, if donation after potential virus exposure is deferred. 
Methods have also been developed to inactivate ZIKV in plasma 
using amotosalen and UVA illumination15. There are issues with 
detection of ZIKV as a false positive dengue NS1 antigen test in a 
traveler to Switzerland was found to have the virus later. Therefore, 
cross-reactivity appears to be an issue in detection16 and this also 
suggests the need for better diagnostics to be developed.
Structural knowledge of the ZIKV proteins may allow us to 
understand exposed epitopes which will facilitate the development 
of specific diagnostic reagents that differentiate it from dengue 
and other flaviviruses. Furthermore, open sharing of the three- 
dimensional arrangement of viral surface proteins could allow the 
mapping of potential neutralizing epitopes, guiding efforts to ration-
ally design effective vaccines. We recently developed a preliminary 
model for ZIKV glycoprotein E based on the dengue virus glyco-
protein E late stage fusion intermediate as a trimer4. We now provide 
homology models of the glycoprotein E based on a dimer structure 
as well as attempts at modeling the other proteins in ZIKV. We have 
also investigated the likely glycosylation sites of the ZIKV envelope 
glycoprotein. Glycosylation may obstruct the binding of antibodies, 
or block access to potential underlying peptide antigens, so 
glycans may be an important consideration in diagnostic and 
vaccine development. Previously, glycosylation analysis using 
several computational tools predicted mammalian N-linked 
glycosylation at Asn-154 in most ZIKV strains17, a site known to 
be important in other flaviviruses. N-glycosylation of the dengue 
envelope glycoprotein at two sites has been shown to mediate 
interactions with DC-SIGN18. Insect cell expression of dengue 
shows both high-mannose and complex glycans19. However, 
flavivirus glycosylation in model systems such as insect cell cul-
ture and mammalian tumor cell lines may not represent the true 
infective insect and mammalian glycoprotein. Mammalian 
O-linked glycosylation was predicted at Thr-245 and Thr-381 
in some isolates17. Yet, reliable prediction is hampered by a lack 
of O-glycosylation consensus sequences and preferences for 
O-glycosylation driven by structural characteristics20.
Understanding the three-dimensional structure of antigenic 
ZIKV proteins may help accelerate the development of antibod-
ies for diagnostics and rationally designed vaccines. In addition, 
the comparison of the assembled surface glycoprotein of ZIKV 
with that of dengue virus may help understand the accessible 
epitopes for the development of anti-flaviral vaccines in general. 
There is considerable prior work including structure-based design 
and virtual screening for dengue, yellow fever and other related 
            Amendments from Version 1
We have added a paragraph and references at the end entitled 
“Notes added while in review” describing all the developments 
since this work was made public in early March 2016. We have 
addressed the reviewer comments and made minor edits to the 
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flaviviruses to develop antivirals to target envelope glycoproteins21–26, 
guanylyltransferase27, capsid protein NS3 helicase, NS2B-NS3 
protease and NS5 polymerase28,29, as well as whole cell screens30 
which have produced many molecules potentially useful against 
ZIKV in vitro. Early work has only tested a small number of 
FDA-approved drugs against ZIKV including (EC50 in parenthe-
sis) interferon (34.3 IU/ml), ribavirin (143 ug/ml), 6-azauridine 
(1.5 ug/ml) and glycyrrhizin (384 ug/ml)31. A recent paper by 
Hamel et al., from 2015 also showed interferon inhibited ZIKV 
replication in primary skin fibroblasts11.
However, the use of compounds against ZIKV should take into 
account the treatment of pregnant women, and many of the potential 
options are unsuitable for use in pregnancy because of toxicity 
and/or teratogenicity. Despite limited human data, the available 
data in animal models suggests caution. Azauridine is highly toxic 
to the fetus in model systems (for example 32). Ribavirin is not 
recommended for use in pregnancy due to embryotoxic and tera-
togenic effects33. Interferon is a potential abortifacient34. We also 
need to consider the treatment of fetus as well as children (that 
might become infected after birth) and the relatively small subsec-
tion of FDA approved drugs that are approved for pediatric use35. 
Therefore, alternative potential drugs for ZIKV are needed. The 
risks of medication use in pregnancy are notable. In particular, 
these include teratogenicity concerns. There is also the issue that 
the disease does not usually pose a direct risk to pregnant women 
themselves, so it’s important any drug, which will not be improving 
their own health, does not damage their health. Pregnancy can also 
create increased risks and liver problems, a particular concern with 
any new drug as it can also affect drug distribution. In pregnancy, a 
ZIKV infection at 13 weeks gestation was coupled with persistent 
virus in a fetus at 32 weeks6. Treatment of symptomatic pregnant 
women may reduce risks of transmission to the fetus. A potential 
drug for ZIKV could also protect fetuses from damage by reduc-
ing transmission in the general population. If the drug appeared to 
reduce the duration of symptoms (which though mild can be annoy-
ing) and in turn reduced viral load, reducing the chance of transmis-
sion, this could benefit them. For example, cholera patients are often 
given antibiotics to reduce transmission. Also those with the flu are 
prescribed Tamiflu/Oseltamivir to reduce the duration of symptoms, 
minimize the severity of symptoms, but its use might also reduce 
transmission of flu in the general population. Since ZIKV has been 
found in semen many weeks after symptoms resolve12, treatment of 
male partners may reduce viral load and reduce the long term risk 
of transmission.
To help accelerate drug discovery through computational analysis, 
we have now developed homology models of ZIKV proteins that 
may serve as potential drug and vaccine targets. To complement 
high-throughput screening efforts, we could perform virtual screen-
ing against the proteins in ZIKV. While there are crystal structures 
for proteins from dengue36,37, yellow fever, West Nile virus and 
other flaviviruses38–44 there are (to date) none for ZIKV. Therefore 
we are limited to generating homology models, although the close 
evolutionary relationships between flavivirus and their component 
proteins and genomes represents a valid approach45.
Methods
Protein sequence alignment
As a prelude to modeling we assessed what 3D structural data 
had significant identity scores to a representative ZIKV polypro-
tein. For this we chose UniProtKB Q32ZE1_9FLAV. While we 
have requested the promotion of this entry to the Swiss-Prot expert 
review level it has been selected as the representative sequence 
for the UniRef90_Q32ZE1 entry that currently clusters 108 ZIKV 
individual sequence entries at 90% (or above) amino acid identity. 
We then performed a BLAST search of this against Protein Data 
Bank (PDB) sequence entries. Protein BLAST analysis was also 
performed for each ZIKV protein sequence46 to identify the closest 
proteins47 and understand potential evolution.
Homology modeling
The amino acid sequences of ZIKV strain (GenBank accession 
number KJ77679148) were retrieved from the GenBank database49 
and used as targets for homology modelling using the SWISS-
MODEL server50,51. The latter performed the target-template 
sequence alignment after searching the putative X-ray template 
proteins in PDB for generating the 3D models for all target 
sequences. The best homology models were selected according to 
Global Model Quality Estimation (GMQE) and QMEAN statis-
tical parameters. GMQE is a quality estimation which combines 
properties from the target-template alignment. The quality esti-
mate ranges between 0 and 1 with higher values for better models. 
QMEAN4 scoring function consisting of a linear combination of 
four structural descriptors as described elsewhere in more detail52,53. 
The pseudo energies returned from the four descriptors are related 
to what we would expect from high resolution X-ray structures of 
similar size using a Z-score scheme. Further, built models were 
exported to the SAVES server Version 454 and their overall stere-
ochemical quality, including backbone torsional angles through the 
Ramachandran plot, was checked according to PROCHECK55. 
Lastly, each model was submitted to an energy minimization pro-
tocol, using the Smart Minimizer algorithm in Discovery Studio 
version 4.1 (Biovia, San Diego, CA).
Site of glycosylation prediction
Mammalian N-glycosylation sites were predicted for glycopro-
tein E by submitting the sequence to web-based tools namely 
N-GlycoSite56, GlycoEP57,58 and NetNGlyc Version 1.059.
Illustration for Zika virion and animation
The Zika virion illustrations were created by combining the 
homology model of the envelope ZIKV glycoprotein E with the 
symmetry data from the dengue virus envelope. PDB ID:1K4R60 
contains the coordinates for three copies of the protein subunit of 
the dengue virus envelope, along with the symmetry data neces-
sary to create the 180-subunit icosahedral structure of the com-
plete viral envelope. The PyMOL Molecular Graphics System, 
Version 1.7.6.0. Schrödinger, LLC. was used to export the 
surface models of the three proteins in .obj format. Then they were 
imported into Lightwave 3D (NewTek, San Antonio, TX) where the 
symmetry data was used to instance copies of the model into the 
icosahedral envelope. The entire structure was copied several times 
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and lighting applied as a surfacing effect to create a visually pleas-
ing composition, and the image rendered out.
The next step was to import into Pymol the homology model of 
the ZIKV envelope protein which was homology modeled using 
PDB ID: 3P54 (from Japanese Encephalitis Virus) as a template. 
A surface model of this protein was exported from Pymol as an 
.obj, and imported into Lightwave in place of the dengue model, 
using the same symmetry operators to create the envelope array. 
Everything else about the picture was left the same (color, 
composition, lighting, etc...) to allow the structural differences to 
be more apparent, and that image rendered out as well.
The last step was to overlay the detailed area of the two images 
and create an animated gif to flip back and forth between the two 
images of ZIKV and dengue, again to allow the differences to be 
more clearly seen. The structure of the Zika virion could be explored 
in a similar manner, using known data from other flaviviruses as a 
guide.
ZIKV glycoprotein E homology model conformation 
comparison
The immature4 and mature (this study) homology models for 
glycoprotein E were compared using the ‘align and superimpose’ 
proteins protocol in Discovery Studio Version 4.1 (Biovia, 
San Diego, CA).
Results
Sequence alignment across flaviviruses
A BLAST search of ZIKV polyprotein against PDB sequence 
entries shows the highest scoring matches with 55–70% sequence 
identity (Supplementary material S1). Protein BLAST analysis 
of the individual ZIKV protein sequences show that many of the 
proteins are similar to the same protein from Spondweni virus in 12 
out of 15 cases (Table 1). Exceptions were: FtsJ which was closer 
to the Murray Valley encephalitis virus, NS1 which was more simi-
lar to dengue virus 3, and glycoprotein E which was closest to the 
dengue virus 1 protein. These results are in general accordance with 
whole sequence analyses45.
Homology modeling
The SWISS-MODEL server was used to generate alignments 
(Supplementary material S2) and homology models for all Zika 
proteins (Table 2, Figure 1, Supplementary material S3). First, we 
selected suitable template protein structures in PDB, observing the 
following criteria: the template should have a high coverage (i.e., 
> 65% of target aligned to template) and sequence identity >30%. 
Then, we used GMQE and QMEAN4 scoring function as an initial 
Table 1. Protein BLAST search results - closest non-ZIKV proteins.
Protein FASTA Closest sequence Coverage E value Identity 
(%)
NS5 AHZ13508.1 (2,772..3,412) RNA-dependent RNA polymerase NS5 [Spondweni virus] 100 0 77
FtsJ AHZ13508.1 (2,575..2,746)
Chain A, Crystal Structure Of The Murray 
Valley Encephalitis Virus Ns5 2’-O 
Methyltransferase Domain In Complex 
With Sah (Monoclinic Form 1)
99 1e91 76
NS4A AHZ13508.1 (2,124..2,267) polyprotein [Spondweni virus] 100 3e68 75
HELICc AHZ13508.1 (1,859..1,975) nonstructural protein NS3 [Spondweni virus] 100 5e61 86
Peptidase S AHZ13508.1 (1,520..1,670) nonstructural protein NS3 [Spondweni virus] 99 2e81 82
DEXDc AHZ13508.1 (1,683..1,828) nonstructural protein NS3 [Spondweni virus] 99 2e79 83
NS2B AHZ13508.1 (1,376..1,502) nonstructural protein NS2B [Spondweni virus] 100 1e56 76
NS2A AHZ13508.1 (1,158..1,372) nonstructural protein NS2A [Spondweni virus] 100 1e64 55
NS1 AHZ13508.1 (796..1,148) polyprotein [Dengue virus 3] 100 2e136 56
E stem AHZ13508.1 (698..794) polyprotein [Spondweni virus] 100 1e38 67
Glycoprotein M AHZ13508.1 (216..290) membrane glycoprotein m [Spondweni virus] 100 1e31 67
Propeptide AHZ13508.1 (126..214) protein pr [Spondweni virus] 100 2e35 61
Capsid AHZ13508.1 (6..122) anchored capsid protein C [Spondweni virus] 96 4e41 68
Glycoprotein E AHZ13508.1 (291..592) AHZ13508.1 (601..693) envelope protein E [Dengue virus 1] 100 3e165 57
NS4B AHZ13508.1 (2,270..2,514) nonstructural protein NS4B [Spondweni virus] 100 2e130 82
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Figure 1. Selected ZIKV NS5 (A), FtsJ (B), HELICc (C), DEXDc (D), Peptidase S7 (E), NS1 (F), E Stem (G), Glycoprotein M (H), Propeptide (I), 
Capsid (J), and Glycoprotein E (K) homology models (minimized proteins) that had good sequence coverage with template proteins 
developed with SWISS-MODEL.
criteria to discriminate good from bad models. Acceptable align-
ment values and higher GMQE and QMEAN4 scores were obtained 
during modeling, suggesting statistically acceptable homol-
ogy models were generated for 11 proteins: NS5, FtsJ, HELICc, 
DEXDc, peptidase S7, NS1, E stem, glycoprotein M, propeptide, 
capsid, and glycoprotein E (Table 2, Figure 1 and Figure 2). The 
Ramachandran plots for these 11 proteins provide further evidence 
of their acceptability (Figure 2). On the other hand, because of low 
GMQE scores and of low coverage observed in X-ray template pro-
teins available in the PDB, homology models for NS4B, NS4A, 
NS2B, and NS2A proteins appeared to have limitations regarding 
active sites and epitopes and they could not be validated.
After building of homology models, we performed an additional 
validation in order to explore stereochemical quality of dihe-
dral angles phi against psi of amino acid residues in modeled 
structures and identify sterically allowed regions for these angles 
using PROCHECK analysis. The results shown in Table 2 and 
Figure 2 reveal that 58.4─70.3% residues of the modeled proteins 
are within the most favored regions (red), 27.1─43.3% residues 
of modeled proteins are within the additional allowed regions 
(yellow), 1.5─6.3% residues of modeled proteins are within the 
generously allowed regions (beige), and only 0.0─6.1% residues of 
modeled proteins are within the disallowed regions (white). These 
results showed that the overall stereochemical properties of the 
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Figure 2. Ramachandran plots for ZIKV NS5 (A), FtsJ (B), HELICc (C), DEXDc (D), Peptidase S7 (E), NS1 (F), E Stem (G), Glycoprotein M (H), 
Propeptide (I), Capsid (J), and Glycoprotein E (K) obtained by PROCHECK, showing the dihedral angles Psi and Phi of amino acid residues. 
Red represents most favored regions; yellow represents additional allowed regions; beige represents generously allowed regions; and white 
areas are disallowed regions.
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generated models were highly reliable and the models could be 
useful to future molecular modeling studies.
Site of glycosylation prediction
Several web-based tools were used for N-glycosylation site pre-
dictions as it provides a more thorough approach. N-GlycoSite56 
suggested N154 as a single N-glycosylation site matching the 
N-X-S/T/C consensus sequence. The same site was identified by 
GlycoEP using BPP settings (binary profile of patterns)57,58 giving 
a score of 0.65/1.00. NetNGlyc59 also gave the same predicted site, 
with a jury agreement of 6/9.
Zika virion compared to dengue virion
A qualitative analysis of the Zika virion (which was constructed 
based on the dengue virion) can be compared to the dengue 
cryo-EM virion (Figure 3) and indicates that Zika appears to have 
slightly more raised ‘pimples’ on the surface. The glycoprotein 
E dimer in ZIKV also has a narrow ‘letter-box’ groove while the 
dengue virion has a bigger ‘pore‘ between the intersection of 
5 dimers (5 fold axis). These differences are considerably more 
apparent in the animation (Supplementary material S4). It is 
important to note that the differences may also be artefacts of the 
homology modeling approach and template used for modeling 
ZIKV glycoprotein E.
ZIKV glycoprotein E homology model conformation 
comparison
The homology models developed using two different templates 
namely the immature protein which was based on the dengue 
crystal structure 4gsx as a template50,71–73 and the mature protein 
which was based on PDB ID:3P54 from Japanese encephalitis 
virus showed a large difference (RMSD 13.47Å) (Figure 4). These 
proteins also demonstrate differences around the pocket used cen-
tered on the residues 270-277.
Discussion
The genus Flavivirus consists of 70 viruses many of which can 
cause severe human disease. There have been few sequence analy-
ses of ZIKV previously in comparison to other flaviviruses. The 
genus Flavivirus produces a monophyletic tree with ZIKV being 
closest to Spondweni virus74 while mosquito borne, tick borne and 
no-vector viruses cluster separately45. A BLAST analysis of all the 
ZIKV proteins in this study suggests for 12 of 15, their closest pro-
tein is in Spondweni virus (Table 1). More often strain sequences 
are compared within ZIKV and these showed variations in the NS5 
gene75 and glycoprotein E17. This is important as it would suggest 
perhaps targeting other proteins would have less issue with resist-
ance or variability due to the strain of ZIKV.
If we are to address ZIKV in the short term while we await a vac-
cine we need to rapidly identify an antiviral, and preferably one 
that can be used against other related flaviviruses. Ideally we would 
need to treat pregnant women and provide them with prophylaxis 
that was safe to them and their fetus. Such an antiviral could also be 
used to reduce transmission in the population in general (by reduc-
ing viral load and symptoms and/or duration). As noted a decade 
ago and is still is true today, no antiviral drug is approved for any 
flavivirus to date76. It has been suggested that one of the ways to 
target these viruses is to interfere with the NS2B/NS3 protease 
complex76. Understanding of flavivirus proteins and other RNA 
viruses has benefited from the EU funded project VIZIER77, 
in particular several West Nile virus, dengue virus and other 
flavivirus structures of NS3 or NS5 were solved during this project 
and allosteric inhibitor sites were identified on NS578. Multiple 
pharmaceutical companies have worked on this target for HCV 
leading to clinical candidates like IDX32079, danoprevir 
(ITMN-191/R7227)80, GS-925681 and others82,83. The only HCV 
protease targeting FDA approved drug is simeprevir, TMC43584,85 
and its use is avoided in pregnancy. Other HCV protease com-
pounds are in clinical trials or submitted for FDA approval including 
Ledipasvir (formerly GS-5885)86. Testing these molecules against 
ZIKV in vitro would be useful.
We recently described 6 steps which could be taken to kick start 
research on ZIKV4, one of which was to develop homology models 
for ZIKV proteins that are similar to those targeted by molecules 
that are also active against the dengue virus. Such an approach 
would then enable docking of compound libraries of known 
Figure 3. Comparison of Zika and dengue virion illustrations.
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antivirals, FDA approved drugs or other compounds4. Ideally 
generating homology models with a single tool may not be 
enough. In particular, for those proteins with low sequence identity 
the use of servers and methods that use threading may be worth-
while (e.g. I-TASSER87–89). However these methods are generally 
only accessible to academics while others are required to license 
the technologies. This is ironic as these technologies were devel-
oped in most cases with NIH and NSF funds. An alternative 
commercial homology modeling approach (MODELLER) was 
also used and generated a NS5 homology model and the top hit 
was also the Japanese encephalitis virus RdRp domain (PDB ID: 
4HDH) compared with PDB ID: 4K6M from SWISS-MODEL61. 
4HDH also includes the ATP and zinc metal where the catalytic 
centers are. The dengue virus 3 polymerase (PDB ID: 4HHJ)90 has 
very high sequence homology and comes up as a potential target 
in MODELLER, which illustrates that all these viral RNA 
dependent polymerases are very similar.
While it is likely that the eventual availability of crystal structures of 
ZIKV proteins would improve the results of docking, the homology 
models described here (Figure 1, Figure 2, Supplementary 
material S2) represent a starting point that can be used to help 
prioritize compounds for testing as described previously4. Proteins 
with templates above 25–40% sequence identity might suggest the 
proteins are related while below this is a twilight zone. Homology 
modeling is thought to fill in the gaps between proteins with x-ray 
structures and those with none91. Experimental testing of homol-
ogy models and crystal structures indicate that a similar enrichment 
rate can be achieved when identifying active compounds in a set 
decoys92. Others have also described homology models that may be 
an excellent alternative when crystal structures are unavailable for 
human GPCRs93,94, and have led to the first identification of inhibi-
tors of the Mycobacterium tuberculosis Topoisomerase I after vir-
tual screening95,96 prior to the crystal structure becoming available97. 
Certainly there are still considerable challenges using homology 
models such as prediction of the correct binding pose98 but there 
are plenty of success stories98–100. While databases of homology 
models exist like MODBASE101 and SWISS-MODEL50,51,71–73 
neither of these have any ZIKV protein homology models at the 
time of writing. There are many structural genomics initiatives and 
yet it would seem there are few if any continuing the work of 
VIZIER working on flaviviruses or emerging viruses.
Availability of structures are important as the structure of the ZIKV 
glycoprotein could be useful for design of antibodies selective for 
the virus which will be critical for the development of diagnostics, 
and understanding antibody binding also for the use of IV immu-
noglobulin in pregnancy and the organization of the epitopes on 
viral proteins may facilitate early work in vaccine development. 
There are further implications for understanding the antibody 
binding epitopes, which are sometimes shared between different 
flaviviruses. Broadly protective vaccines for flaviviruses may allow 
the simultaneous targeting of ZIKV and related viruses such as 
dengue102. Understanding glycosylation is therefore important. 
To date Asn-154 is mentioned in Faye et al.,17 as a glycosylation 
site, as are Thr-170 (mucin type O-linked glycosylation) and other 
mucin sites at Thr-245 and Thr-381. Other probably O-GlcNAC 
attachment sites (Ser-142, Ser-227, Thr-231, Ser-304, Thr-366, 
and Thr-381) were also predicted. Our analysis of N-glycosylation 
with 3 different websites suggest Asn-154 also as a likely site of 
N-glycosylation in agreement with dengue virus18.
Cryo-EM has been used to show how glycoprotein E dimers 
arrange on the surface of virions for flaviviruses including tick-
borne encephalitis virus103, West Nile virus104, dengue virus 1105 
and dengue virus 4106 (Supplementary material S3). The early work 
on the tick-borne encephalitis virus103 suggested 30 dimers on the 
surface and also pointed to how the glycoprotein E dimers can reor-
ganize under low pH to form a trimer. The packing of the dimers 
in the dengue virion is different to tick-borne encephalitis with the 
glycoprotein E dimers showing 30 ‘herringbone rafts’ each contain-
ing three dimers to result in 180 copies of the protein67,107. West 
Nile virus again has a different arrangement with 60 trimers shown 
in the structure of the immature virus104 (Supplementary material S4). 
Even between the dengue serotypes 1, 2 and 4 for which there 
are cryo-EM structures105,106 it is apparent while the rafts are very 
similar (as are the sequence identities [60%]) there is a different 
charge distribution of the surface of each. Dengue serotype 2 had 
larger continuous patches of positive charges which was proposed 
to enable improved binding to heparan sulfate. This might also be 
the case for ZIKV in that the charge pattern is again different and 
could be key for vaccine development. The availability of virion 
structures makes it feasible to understand structure function of the 
complete virus such as assessment of membrane curvature and how 
organization of membrane proteins affects this43.
A model of the Zika virion was constructed as an illustration using 
the homology model of the glycoprotein E dimer (Figure 3). While 
the combined protein sequence of glycoprotein E and the immu-
noglobulin like domain is closest to dengue virus 1 (57 percent 
identity, Table 1) the closest template was for the crystal structure 
of the Japanese encephalitis virus envelope protein (53.12 percent 
identity, Table 2). This would suggest the virion should more 
closely resemble that of dengue virus 1, while producing a homol-
ogy model based on a more distant virus might not be ideal. The 
homology model of glycoprotein E developed for the mature con-
formation in this study is significantly different from that developed 
previously for the immature conformation (Figure 4). The proposed 
binding site centered around residues 270-277 appears shallower in 
the mature conformation and this would certainly affect the kinds 
of molecules that it could interact with. It might also point to the 
need to interfere with the immature conformation as preferable 
Figure 4. Overlap of ZIKV homology models for glycoprotein E, 
Yellow = mature conformation  (this study) compared with  the 
immature conformation (red)4.
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versus the mature conformation. Ultimately perhaps this model of 
the Zika virion could help us understand how drugs could access 
the virus. Viruses affecting pregnancy, like say Varicella which 
causes microcephaly and other developmental problems106,107, are 
often treated with IV immunoglobulin, i.e. antibodies, as well as 
antivirals to reduce the effect of the virus (or to avoid infection if 
given soon after exposure). The models could help us design com-
bination approaches possibly targeting multiple proteins that might 
prevent drug resistance from occurring also.
Does having the homology models and the virion illustration help 
understand function? Well, the surface charge pattern might be 
inferred from the homology model and could be compared with 
dengue and other filoviruses for which there are cryo-EM struc-
tures. This may in turn present opportunities for vaccine design 
by indicating accessible surfaces and properties, allowing map-
ping of epitopes, design of accessible fragments and peptides for 
vaccine/diagnostic design. Vaccines themselves might be the only 
way to avoid the inevitable, otherwise, simply reducing the spread 
of ZIKV would just delay it. Women ultimately may just want to 
‘get it over with’ and have ZIKV before they get pregnant and hope 
there is lasting immunity.
In summary, in the absence of crystal structures for any of the 
proteins comprising the ZIKV, we are left to attempt to con-
struct homology models which we have done using the freely 
available SWISS-MODEL server. Further preparation of these 
models required freely available and commercial tools. In the case 
of the ZIKV glycoprotein E homology model, this has the added 
benefit of enabling the construction of a full virion. By comparing 
the Zika virion to the existing structures for other flaviviruses we 
can see similarities and differences on the surface (Supplementary 
material S4, Supplementary material S5). This relatively crude 
approach could help to understand how we might develop antivi-
rals and vaccines against it. In addition we now provide homology 
models as a starting point for (small and large scale) docking stud-
ies and further evaluation which may complement other modeling 
efforts for ZIKV110. Ultimately the results of their use can be 
compared with using ZIKV crystal structures once generated.
Notes added while in review
Since the initial publication of this article several cryo-EM 
and crystal structures have been published for ZIKV, including 
candidate targets for inhibitor medicinal chemistry optimization and 
vaccine design112–115. Detailed comparisons between our homology 
models and the experimental structures will be the subject of 
future comparisons with the homology models described herein. 
It should be noted that the prediction for the site of glycosylation 
of glycoprotein E was experimentally verified by Sirohi et al.112, 
We would also point out the utility of this work through the World 
Community Grid we have started the OpenZika project116–118 
which is using these homology models, template structures and 
crystal structures to dock millions of molecules (with AutoDock 
Vina119–121) to identify compounds for testing against Zika with 
collaborators. Both the docking and activity screening results 
(http://openzika.ufg.br/experiments/) will be open to the commu-
nity and published in due course. An obvious utility of this entire 
exercise is that, by testing, iterating and tweaking the methodolo-
gies each time (e.g. between Ebola and ZIKV) the open science 
community becomes better prepared for the next global pathogen 
emergency.
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Response: Dear Prof Botta, thank you for taking the time to review and constructively
comment on this manuscript.
Infections by Zika virus are seriously preoccupying the population and governments of endemic
countries, with particular attention to pregnant women. Indeed, the most serious complications of
infections by Zika virus have been observed in pregnant women (i.e. microencephalic fetus).
However, the evidence that pregnant women are most affected by Zika virus infection, set some
difficulties in developing focused therapeutic strategies, as nicely discussed by the authors.
However, in this respect, which is the scenario proposed by authors for a candidate inhibitor of
Zika virus replication. Why this molecule should be useful, and how pregnant women could deal
with the administration of the drug?
 
Response – If we understand the question correctly - any drug for Zika should be safe for
all including pregnant women. If they have a Zika infection it would be important to
eradicate the virus as soon as possible so that the fetus perhaps is not exposed to the
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all including pregnant women. If they have a Zika infection it would be important to
eradicate the virus as soon as possible so that the fetus perhaps is not exposed to the
virus.
 
Overall, the work is well written and organized in a clear and rational way, even if no experimental
validation of the work carried out  is proposed.in silico
 
Response: This work was initiated in Feb 2016, months before the first crystal structures
and experimental in vitro systems were published. Our goal was to build protein models
that we would eventually use and which others could use in parallel, to start
docking-based virtual screening and identify VS and experimental hits, to initiate the drug
discovery cascade.
 
Accordingly, conclusions of this work are merely speculative.
 
Response: A modeling study, by definition is speculative and does not claim otherwise.
 However, in good faith, we provided models which did not exist. The fact that they have
since gone on to form the basis of the OpenZika Project (manuscript submitted, 
) and have been used to suggest compounds which are now beinghttp://openzika.ufg.br
tested argues for their utility. Notwithstanding, we acknowledge that Zika protease,
helicase and glycoprotein E experimental structures have now been elucidated and
deposited in PDB. 
 
My major concern is on the usability of the protein structures for drug design or virtual screening,
as claimed by the authors in the abstract and discussion. Indeed, sequence identity between
template and target sequences is rather low in some cases (< 60 %).
 
Response – As expected for the enzyme functions, the local active site identity and
similarity scores are higher than indicated by the full-length identity %. Thus, a
reasonable pocket model for docking is the primary goal, not the structural accuracy for
the whole protein.  We would also add that any team using our models would doubtless
take a pragmatic approach that would include running various types of internal controls
for virtual screening studies and confirmatory screening experiments (e.g. running the
Dengue virus templates alone and checking for enrichment of established Dengue actives
against the purified proteins). They would also probably prioritize their effort on the
models with highest template similarity. Note also that, the first reviewer Dr. Fiser accepts
that our similarity values are high enough for reliable modelling.   
 
Moreover, the atomistic detail of the active site and its conformation may vary noticeably in the
models depending on the program used, the force field, the level of refinement (algorithm, steps,
solvent model, …) and the quality of the template structure.
 
Response – We agree that this is one of the challenges with this approach, but there were
no other options without a single crystal structure for Zika protein when we started this
work and submitted it.
 
All these variables should be taken into consideration by the authors, and the refinement of 3D
models should be at least attempted or discussed in deeper details. In my personal opinion, details
on the conservation rate, sequence identity and structural similarity of the binding sites would be
more helpful for drug design purposes.
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Response: We agree with your point. We are now refining the 3D models using molecular
dynamics simulations. However, this will be the subject of work on going, taking an in
depth approach to each structure and comparison to crystal structures when available.
Our main goal in this paper which we submitted in Feb 2016 (and made available early
March) was to provide the scientific community with the first 3D models of Zika proteins.
Finally, an experimental validation of at least one of the structures modeled by authors (i.e. the
most promising target for drug designing studies) should be provided. In fact, analysis with
PROCHECK or the use of numerical scores is not sufficient to validate a 3D structure generated by
homology modeling.
 
Response – We agree that the experimental validation of the protein structures is of
upmost importance in drug discovery programs, but this was not the scope of this paper.
Again, our main goal was to generate homology models for the key proteins, which none
crystal was available at the moment of the submission, and these models could be taken
to initiate ZIKV antiviral drug discovery using both high throughput screens as well as
structure-based design. Moreover, these structures were the core to initiate the World
Community Grid project called OpenZika (
, which is a globalhttps://www.worldcommunitygrid.org/research/zika/overview.do)
research project to accelerate the discovery of an antiviral against the Zika virus. 
PROCHECK was originally developed to evaluate the stereochemical quality of
experimentally determined protein structures (Laskowski R A, MacArthur M W, Moss D S,
Thornton J M (1993). J. App. Cryst., 26, 283-291; Morris A L, MacArthur M W, Hutchinson E
G & Thornton J M (1992). Proteins, 12, 345-364). However, PROCHECK has been widely
used and reported in the literature to check the stereochemical quality of homology
models, to provide numerical scores that can evaluate the statistical quality of the
generated 3D protein models (See bellow the list of summarized most recent literature).  It
is a quality assessment criterion and is not related to experimental validation. 
 
Papers reporting the use of PROCHECK for assessing the stereochemical quality of
homology models:
J Biomol Struct Dyn. 2016 Apr 4:1-19 [DOI: 10.1080/07391102.2015.1117397].
Curr Cancer Drug Targets. 2015;15(9):822-35 [PMID: 26567883].
Interdiscip Sci. 2015 Aug 15. In Press [DOI: 10.1007/s12539-015-0121-z].
Onco Targets Ther. 2015 Jul 30;8:1923-30 [DOI: 10.2147/OTT.S84200].
Interdiscip Sci. 2016 Mar;8(1):41-52 [DOI: 10.1007/s12539-015-0269-6].
J Mol Model. 2015 Mar;21(3):37. [DOI: 10.1007/s00894-015-2586-4]. 
 
There is a high risk that molecular docking towards a low-resolution structure could provide
unrealistic results.
 
Response – Yes we absolutely agree, but when we started this we had no crystal
structures we had to start somewhere as a means to start to filter compounds rather than
random HTS.
Our work has also correctly predicted the glycosylation site for glycoprotein E one of the
first structures crystallized. Moreover, we have compared our models with the
crystallographic structures, when they were made available. The RMSD values ranged
from 0.72 to 1.8 Å, for the structures of NS1, NS3, glycoprotein E and NS2/NS3 proteins.
We have also optimized the 3D models and the MolProbit scores ranged from 1.28 to 2.81
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We have also optimized the 3D models and the MolProbit scores ranged from 1.28 to 2.81
Å. MolProbit is a score that combines the clashscore, rotamer, and Ramachandran
evaluations into a single score, normalized to be on the same scale as X-ray resolution.
Therefore, we are optimistic that our models are reliable to start a docking-based virtual
screening program in the search of a new antiviral drug, which we already initiated.
 
The paper can be accepted after revision.
 
Response – Thank you!
 
 
 No competing interests were disclosed.Competing Interests:
 11 April 2016Referee Report
doi:10.5256/f1000research.8833.r13009
 Andras Fiser
Albert Einstein College of Medicine, Bronx, NY, USA
The paper describes homology models of 15 proteins encoded in the genome of Zika virus that are built
by the SWISSmodel web server. A glycolysation site was also identified. Using the models of Zika
glycoprotein E a complete structural model of the virion was constructed.
The practical results of the work are the 11 high quality homology models that could be used in the future
for structure based drug development. I believe an interested researcher will initiate time consuming
follow up studies with these models only if there is a substantial added value.
These models passed quality assessment criteria according to the authors. However a number of
successful models (passing similarly well the same quality requirements) can be generated that will differ
in small but essential details by e.g. side chain placement, or loop conformations. However, these
differences can have a dramatic effect on the outcome of subsequent drug docking trials. These
alternative models can be obtained when different softwares are used, as the authors allude to it, e.g.
using Modeller vs SWISSModel, as these use different forcefields and restraints to generate models.
Therefore, the authors should consider providing a more insightful result by running several different
modeling programs or using alternative templates (see 4., below), and comparing the results, identifying
similarly modeled parts of these models and providing a set of possible solutions for subsequent studies.  
A battery of model quality checks were performed and additional energy minimization. However the
overall high sequence identities between the target proteins and their respective templates (55% and up,)
ensure that these models are highly reliable.  
Therefore the extensive reporting on Ramachandran plots (Figure 3) is not adding much to the
results, it can be transferred to supplementary material.
 
Similarly, Table 2 can be shrunk by eliminating many details of PROCHECK results.
 
However the information on templates should be reported in the table, instead listing them
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However the information on templates should be reported in the table, instead listing them
extensively in the text.
 
Template selection was purely based on sequence similarity requirements. Given how influential
this step and how few cases require attention in this specific study, one could imagine to perform a
more detailed quality check of potential templates. For instance, if several templates are available
in the same sequence identity range, one should consider picking the one wit the best resolution
etc. Figure 4 exposes this dilemma where two isoforms of the same template can results models
with very significant differences.
 
Energy refinement rarely, if ever, improves model quality and its use here should be better justified.
 
Some statements require attention e.g in Abstract: “Eleven out of 15 models pass our criteria for
selection”. What selection? This must be referring to quality or accuracy of models, and should be
rephrased accordingly.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
Author Response 25 Aug 2016
, Collaborations in Chemistry, USASean Ekins
Dear Prof Fiser, thank you for taking the time to review and constructively comment on
this manuscript.
 
The paper describes homology models of 15 proteins encoded in the genome of Zika virus that are
built by the SWISSmodel web server. A glycolysation site was also identified. Using the models of
Zika glycoprotein E a complete structural model of the virion was constructed.
The practical results of the work are the 11 high quality homology models that could be used in the
future for structure based drug development. I believe an interested researcher will initiate time
consuming follow up studies with these models only if there is a substantial added value.
 
Response: Thank you! We would also point out the utility of this work is not only reflected
in the high level of accesses, downloads and citations, but also for initiating the
World Community Grid as the OpenZika project, which was launched in May, 2016
(https://www.worldcommunitygrid.org/research/zika/overview.do)
These models passed quality assessment criteria according to the authors. However a number of
successful models (passing similarly well the same quality requirements) can be generated that will
differ in small but essential details by e.g. side chain placement, or loop conformations. However,
these differences can have a dramatic effect on the outcome of subsequent drug docking trials.
These alternative models can be obtained when different softwares are used, as the authors allude
to it, e.g. using Modeller vs SWISSModel, as these use different force fields and restraints to
generate models. Therefore, the authors should consider providing a more insightful result by
running several different modeling programs or using alternative templates (see 4., below), and
comparing the results, identifying similarly modeled parts of these models and providing a set of
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running several different modeling programs or using alternative templates (see 4., below), and
comparing the results, identifying similarly modeled parts of these models and providing a set of
possible solutions for subsequent studies.  
 
Response: We would agree that certainly an exhaustive analysis of different methods was
not undertaken. That was not our goal. We attempted to build models that we could then
put into practice and provide to the community for them to use knowing the possible
caveats.
A battery of model quality checks were performed and additional energy minimization. However
the overall high sequence identities between the target proteins and their respective templates
(55% and up,) ensure that these models are highly reliable.  
 
Response: Thank you!
Therefore the extensive reporting on Ramachandran plots (Figure 3) is not adding much to
the results, it can be transferred to supplementary material.
Response: Actually many publications use these plots and they may provide some
insights on model quality so we have opted to retain them in the body of the
manuscript, as the F1000Research journal does not have a limit for figures.
 
Similarly, Table 2 can be shrunk by eliminating many details of PROCHECK results.
Response: This is an internet publication we are not constrained by pages or page
charges and these numbers are informative to readers. 
 
However the information on templates should be reported in the table, instead listing them
extensively in the text.
Response: We agree and we believe that it is neater and more accessible in a table.
Therefore, we have added the information on templates in Table 2 and removed this
information from the text.
 
Template selection was purely based on sequence similarity requirements. Given how
influential this step and how few cases require attention in this specific study, one could
imagine to perform a more detailed quality check of potential templates. For instance, if
several templates are available in the same sequence identity range, one should consider
picking the one with the best resolution etc. Figure 4 exposes this dilemma where two
isoforms of the same template can results models with very significant differences.
Response: We totally agree – some decisions had to be made as a trade-off to get
the models built in a reasonable time to put into use. We could have spent months
building models by which time the x-ray structures would have been out. We had
models of the proteins and the virion at least 1 month before the first cryo-EM
structure. One month is a long time in drug discovery, in which we could be finding
molecules for testing.
 
Energy refinement rarely, if ever, improves model quality and its use here should be better
justified.
Response: We totally agree with you, Dr. Fiser. Energy minimization does not
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Response: We totally agree with you, Dr. Fiser. Energy minimization does not
improve model quality. The word “refined”in the paper was a mistake and we have
corrected it now. We are using some servers, such as KoBaMIN server, to perform
structure refinement and to improve models quality, but this will be subject of
another manuscript. Our main goal in this first paper was to provide the scientific
community with homology models for the key proteins, which none crystal was
available at the moment of the submission of this paper, and these models could be
taken to initiate ZIKV antiviral drug discovery using both high throughput screens
as well as structure-based design. Moreover, these structures were the core to
initiate the World Community Grid project called OpenZika (
, which is a globalhttps://www.worldcommunitygrid.org/research/zika/overview.do)
.research project to accelerate the discovery of an antiviral against the Zika virus
 
Some statements require attention e.g in Abstract: “Eleven out of 15 models pass our
criteria for selection”. What selection? This must be referring to quality or accuracy of
models, and should be rephrased accordingly.
Response: OK Thank you! Changed to -  Eleven out of 15 models pass our model
quality criteria for their further use.
 No competing interests were disclosed.Competing Interests:
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